# Safety and Efficacy Evaluation of IM19 Cells

> **NCT03344705** · PHASE1 · UNKNOWN · sponsor: **Beijing Immunochina Medical Science & Technology Co., Ltd.** · enrollment: 20 (estimated)

## Conditions studied

- Hematological Malignancies

## Interventions

- **BIOLOGICAL:** IM19 CAR-T
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03344705
- **Lead sponsor:** Beijing Immunochina Medical Science & Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-21
- **Primary completion:** 2020-10-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03344705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03344705, "Safety and Efficacy Evaluation of IM19 Cells". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03344705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*